Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Fintel reports that on February 18, 2025, William Blair upgraded their outlook for Parsons (NYSE:PSN) from Market Perform to ...
Investment analysts at William Blair reduced their Q1 2025 EPS estimates for shares of Zoetis in a note issued to investors ...
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
Stock analysts at William Blair cut their Q2 2025 earnings per share estimates for Generac in a research report issued to clients and investors on Thursday, February 13th. William Blair analyst B.
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
William Blair analyst Dylan Becker upgraded Manhattan Associates (MANH) to Outperform from Market Perform without a price target The firm says its cloud model analysis and additional color on the ...
William Blair last night initiated coverage of Rubrik (RBRK) with a Market Perform rating. While Rubrik’s growth runway “ooks long and its ...
Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (the “Company”) today announced the commencement ...